title: Fixing the skin barrier: past, present and future--man and dog compared.
abstract: Skin barrier dysfunction exists in both human and canine atopic dermatitis, leading to increased water loss and potentially facilitating allergen penetration and sensitization. Both lipid (e.g. ceramides) and protein (e.g. filaggrin) abnormalities have been described. Some are genetically inherited (e.g. filaggrin mutations are one of the major risk factors in humans) and some are secondary and linked to inflammation. In humans, numerous studies have shown efficacy of emollients and moisturizers in barrier restoration, and this approach has been for years the mainstay of therapy. Recently, this strategy has shown promise as a preventative function. In veterinary medicine, evidence regarding skin barrier impairment is rapidly building. Decreased ceramides and filaggrin (in some subsets of dogs) have been described. Altered metabolism of ceramides has also been proposed. Despite these preliminary data and the availability of products marketed to improve the skin barrier, evidence regarding the clinical benefit of skin repair intervention is still limited. Preliminary studies have demonstrated that topical application of fatty acids and ceramides and systemic administration of fatty acids improve lipid deficiencies in the skin of dogs with atopic dermatitis, but limited clinical evidence exists. Disease remission in humans is paralleled by an improved skin barrier, both with calcineurin inhibitors and glucocorticoids. In veterinary medicine, a preliminary study on ciclosporin and prednisone failed to detect significant improvement of water loss, while successful immunotherapy correlated with an improved skin barrier. Controlled, large studies are needed to address the question of which skin repair approach is clinically most effective and whether this can be used as a preventative strategy.
authors: Department of Small Animal Clinical Sciences, College of Veterinary Medicine, 2015 SW 16th Avenue, University of Florida, Gainesville, FL 32610, USA. marsella@ufl.edu
authors: Rosanna
authors: R
authors: Marsella
mesh_terms: D000287:Administration, Topical; D000818:Animals; D065095:Calcineurin Inhibitors; D004285:Dogs; D004643:Emollients / Q000008:administration & dosage*; D000091344:Filaggrin Proteins; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D058427:Hygroscopic Agents / Q000008:administration & dosage; D012869:Skin Absorption; D017592:Skin Care / Q000379:methods; D012871:Skin Diseases / Q000628:therapy / Q000662:veterinary*; D012879:Skin Physiological Phenomena; D014867:Water / Q000378:metabolism*; D014870:Water Loss, Insensible / Q000187:drug effects
chemical_list: D065095:Calcineurin Inhibitors; D004643:Emollients; C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D005938:Glucocorticoids; D058427:Hygroscopic Agents; D014867:Water